Target intelligence / Profile preview

Myc proto-oncogene protein (c-Myc (or MYC))

Target
c-Myc (or MYC)
Molecular classification
Transcription factor, Basic helix–loop–helix (bHLH) family, Proto-oncogene
01

Overview

Myc proto-oncogene protein (commonly called c-Myc or MYC) is a basic helix-loop-helix leucine zipper transcription factor encoded by the MYC gene. It is a key regulator of cell growth, proliferation, and metabolism, and controls expression of a wide array of genes by binding specific DNA sequences. As a proto-oncogene, MYC is frequently dysregulated in cancer, where its constitutive expression promotes uncontrolled cellular proliferation and tumorigenesis. Because of its central role in cancer, MYC is a highly studied but challenging therapeutic target, with most drug strategies focused on indirect inhibition via mRNA targeting or protein-protein interaction disruption[1][5].

Other names
c-MycMYCbHLHe39proto-oncogene c-Mycavian myelocytomatosis viral oncogene homolog
02

Mechanism of action

Inhibitors attempt to block MYC expression, promote MYC degradation, disrupt protein-protein interactions, or block translation of MYC mRNA[1]

03

Biological functions

Regulation of cell proliferationcell cycle progressionapoptosiscell growthcellular differentiationstem cell maintenance
04

Disease associations

Cancer (including Burkitt lymphoma, colon cancer, breast cancer, lung cancer, cervical cancer, stomach cancer)Other (contributes to reprogramming somatic cells to induced pluripotent stem cells)
05

Safety considerations

On-target toxicity due to MYC’s critical role in normal cell functiondifficulty developing direct inhibitorspotential for broad effects in normal proliferating cells[1]
06

Interacting drugs

None approved directly targeting c-Myc; approaches include indirect inhibitors, antisense oligonucleotides, or molecules targeting MYC mRNA or protein stability[1]
07

Biomarkers

MYC expression/amplification status as a biomarker for aggressive cancer subtypes, especially in Burkitt lymphoma

Beyond the preview

Go deeper on Myc proto-oncogene protein (c-Myc (or MYC)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myc proto-oncogene protein (c-Myc (or MYC)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call